Welcome to our dedicated page for Harvard Apparatus Regenerative Technology news (Ticker: HRGN), a resource for investors and traders seeking the latest updates and insights on Harvard Apparatus Regenerative Technology stock.
Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) is a clinical-stage biotechnology company that reports it is developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs. News about HRGN often centers on its cell-therapy platform, which uses a patient’s own stem cells to regenerate and restore function to damaged organs, and on its lead product candidate, the Cellspan Esophageal Implant.
Company updates have highlighted clinical milestones, including FDA approval of a phase one and phase two clinical trial to study repair of esophageal damage in adults, activation of Mayo Clinic and the University of Michigan as clinical trial sites, and engagement of IQVIA as contract research organization. HRGN’s news flow also covers collaborations, such as a partnership with the Children’s Hospital Capital Institute of Pediatrics in Beijing, China to develop treatments for Esophageal Atresia, a research agreement with the McGowan Institute for Regenerative Medicine to study colon repair after colectomy, and a Sponsored Research Agreement with a Yale School of Medicine physician to explore uterine tissue repair.
Investors following HRGN can also find announcements about financing transactions, including private placements and PIPE financings intended to support clinical development and pipeline expansion, as well as updates on the company’s longevity product business operated through a Hong Kong subsidiary. In addition, the company’s news has described its reported world’s first successful regeneration of the esophagus in a patient with esophageal cancer and related scientific publications.
This news page aggregates these types of developments, providing a single location for company-issued financial results, clinical and research updates, collaboration announcements and capital markets activity related to Harvard Apparatus Regenerative Technology.
Summary not available.